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Abstract 
Background: Being one of the most common nasal diseases, chronic rhinosinusitis (CRS) is subdivided into CRS with 
nasal polyps (NP) and CRS without nasal polyps (CRSsNP). CRSsNP presents itself with a TH1 milieu and neutrophil infil-
tration, while NP is characterised by a mixed TH1/TH2 profile and an influx of predominantly eosinophils, plasma cells 
and mast cells. For the purpose of discovering disease-specific cytokine profiles, the present study compares levels of 
mediators and cytokines in nasal secretions between CRSsNP, NP, and healthy controls.
Methods: The study included 45 participants suffering from NP, 48 suffering from CRSsNP and 48 healthy controls. 
Allergic rhinitis constituted an exclusion criterion. Nasal secretions, sampled using the cotton wool method, were 
analysed for IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, IL-8, GM-CSF, G-CSF, IFN-γ, MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES, 
and for ECP and tryptase, using Bio-Plex Cytokine assay or ELISA, respectively.
Results: Elevated levels of IL-5, IL-17, G-CSF, MCP-1, MIP-1α, MIP-1β, ECP, and tryptase, as well as decreased levels of 
IL-10, IL-12, IL-13, and IFN-γ were detected in NP. CRSsNP presented increased levels of RANTES and MIP-1β while IL-13 
was decreased. No differences between the three groups were found for IL-4, IL-8, GM-CSF, and eotaxin.
Conclusions: The present work suggests a disequilibrium of TH1 and TH2, together with a down-regulation of regula-
tory T lymphocytes and up-regulated TH17 in NP. Moreover, elevated levels of diverse mediators represent the activa-
tion of various inflammatory cells in this disease entity. The inflammation in CRSsNP, however, is only weakly depicted 
in nasal secretions. Therefore, cytokines in nasal secretions may provide helpful information for differential diagnosis.
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Background
Chronic rhinosinusitis (CRS) is one of the most common 
nasal diseases, affecting 5 % of the Canadian population 
and 11 % of Europeans [1, 2]. Deteriorating both physi-
cal and mental health, CRS significantly impairs patients’ 
quality of life and imposes immense costs on the public 
health system [3, 4]. CRS is characterised by an inflam-
mation of the nose and paranasal sinuses for more than 
12 weeks, causing nasal obstruction and discharge, facial 
pain, and reduction of smell [5]. By nasal endoscopy, this 
disease is subdivided into CRS with nasal polyps (NP) 
and CRS without nasal polyps (CRSsNP) [5].
Nasal polyps manifest themselves macroscopically as 
grey masses, prolapsing into the nasal cavity. In histologi-
cal sections, oedema, pseudocysts, and a colourful infil-
trate of inflammatory cells are seen. In contrast, CRSsNP 
is characterised by fibrosis and basement membrane 
thickening [6].
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The pathophysiology of CRS is not yet well understood. 
Although CRS may be associated to genetic or systemic 
diseases such as cystic fibrosis or sarcoidosis, the major-
ity of the CRS patients seems to suffer from idiopathic 
disease [7]. Concerning the aetiopathology, local and sys-
temic host factors as well as environmental factors have 
been discussed [8]. However, hypotheses about impaired 
innate immunity, fungi, or superantigens remain to 
be verified. Atopic diseases are more frequent in CRS 
patients than in the general population, and allergy as an 
associated or deteriorating factor has also been discussed 
[9]. Yet, a definitive answer is owing.
According to reported cell and cytokine patterns, 
CRSsNP and NP seem to be different disease entities. 
CRSsNP is characterised by a TH1 milieu and neutro-
phils. NP, on the other hand, shows a mixed TH1/TH2 
profile with increased numbers of eosinophils, plasma 
cells and mast cells [6, 10]. However, this only applies 
to the majority of the Caucasian NP patients; Asian NP 
patients have been reported to show a TH1/TH17 polari-
sation, while the T cell patterns of CRSsNP were similar 
in both races [6, 11, 12].
The present work compares cytokines in nasal secre-
tions of NP and CRSsNP patients to those of healthy 
subjects. In the present study, we wanted to study CRS 
in pure form. As interference between the pathophysi-
ological processes of allergic rhinitis and CRS is conceiv-
able, allergy testing was performed to exclude allergic 
patients from the study. Levels of cytokines were inves-
tigated in order to determine whether the pathophysi-
ology of CRS is depicted in nasal secretions. Our study 
focusses on two major aspects: the regulation of the T 
cell subsets TH1, TH2, TH17, and regulatory T cells (Treg), 
represented by levels of interleukin (IL)-4, IL-5, IL-10, 
IL-12, IL-13, IL-17, and Interferon (IFN)–γ, and the 
regulation and activation of inflammatory cells such as 
granulocytes and mast cells by levels of IL-5, IL-8, gran-
ulocyte–macrophage colony-stimulating factor (GM-
CSF), granulocyte colony-stimulating factor (G-CSF), 
eotaxin, “regulated on activation, normal T cell expressed 
and secreted” (RANTES) protein, macrophage inflamma-
tory protein (MIP)-1α, MIP-1β, monocyte chemotactic 




141 volunteers (64 males, 77 females, mean age 
41 ± 15 years) participated in the present study. Clinical 
history was taken by one of the investigators. All subjects 
were tested for allergy to aeroallergens with the in vitro 
allergy screening test Sx1 (Phadia, Freiburg, Germany). 
Based on a fluorescence-enzyme-immunoassay (FEIA) 
this method tests for IgE to inhalant allergens in partici-
pants’ sera. Volunteers presenting a history of allergy or a 
positive Sx1 were excluded from the study.
Any medication concerning the nasal disease during 
6  weeks prior to the examination constituted an exclu-
sion criterion, particularly anti-inflammatory medica-
tion such as topical nasal steroids. To detect nasal polyps 
and exclude patients with signs of purulent rhinitis, nasal 
endoscopy was performed in all volunteers. For ethical 
reasons, X-ray computed tomography (CT) scanning was 
only performed if indicated for medical care, but not for 
the purpose of this study.
NP (n  =  45) was determined by the patient’s history 
and the presence of endoscopically visible polyps in the 
nasal cavity, the paranasal sinuses, or both.
CRSsNP (n = 48) was determined clinically by typical 
complaints in the patient’s history such as midfacial pain 
or pressure, postnasal drip, nasal obstruction, or reduc-
tion of smell. Inspection of the nose and nasal endoscopy 
revealed the picture of a chronic mucosal inflammation 
in the absence of polyps.
Healthy controls (n  =  48) presented no history of 
inflammatory nasal complaints and normal findings in 
the endoscopic examination.
The study was approved by the ethics committee of 
the medical faculty of Ludwig-Maximilians-University 
in Munich, Germany, and written informed consent was 
obtained from all participants.
Biochemical and immunological methods
Nasal secretions were gained and processed with minor 
modifications as described by Rasp and co-workers [13]: 
For the sampling of nasal secretions, small cone-shaped 
cotton wool pieces (absorbent cotton, Hartmann, Hei-
denheim/Brenz, Germany) with a length of about 3 cm 
and a diameter of about 6  mm were used. After posi-
tioning the cotton wool pieces in the middle meatus of 
the nose, they were left in place for 20 min and subse-
quently centrifuged (+4 °C, 2000g) on a sieve for 10 min 
[14].
Diluted 1:5, all samples were analysed for IL-4, IL-5, 
IL-10, IL-12, IL-13, IL-17, IL-8, GM-CSF, G-CSF, IFN-γ, 
MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES using 
a human cytokine 17-plex panel (Bio-Plex Cytokine 
Assay, Bio-Rad Laboratories, Hercules, California). This 
cytokine assay uses fluorescently-addressed polystyrene 
beads with conjugated capture antibodies directed to 
the aforesaid cytokines. After washing, a fluorescently 
marked detection antibody builds an immunoassay with 
the cytokine. For analysis, two lasers excite the fluoro-
chromes: one for classifying each bead, the other for 
quantifying the amount of analyte bound [15]. The detec-
tion threshold was 0.5 pg/ml.
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ECP and tryptase were measured by ELISA (UniCAP-
FEIA, Phadia, Freiburg, Germany). Detection levels were 
10 ng/ml for ECP, and 5 ng/ml for tryptase.
Statistics
SigmaPlot for Windows version 11.0 software (Systat 
Software, San José, California, USA) was utilised for sta-
tistical evaluation and graphical presentation. As all data 
failed normality testing (Shapiro–Wilk), the Kruskal–
Wallis one way analysis of variance (ANOVA) on Ranks 
was used, testing for statistically significant difference in 
the median values among the three groups. To isolate the 
group or groups that differ from the others, the all pair-
wise multiple comparison procedures (Dunn’s Method) 
was used in the following step. To reduce the false discov-
ery rate, the method of Benjamini and Yekutieli was used 
[16]. Data are given as median and range. For graphic 
presentation, data are displayed in a box plot with the 
median (horizontal line within the box), the 25th and 
75th percentile (boundary of the box), and the 10th and 
90th percentile (whiskers above and below the box). Sig-
nificances are graphically represented between the corre-
sponding plots: * indicates p value <0.05, ** p value <0.01, 
and *** p value <0.001.
Results
In total, 141 participants were included in this study, 45 
people suffering from NP (28 males, 17 females; mean 
age 42 ± 15 years), 48 suffering from CRSsNP (18 males, 
30 females; mean age 42 ± 15 years) and 48 healthy sub-
jects (18 males, 30 females; mean age 40 ± 16 years).
The levels of TH2 related cytokines presented an inho-
mogeneous picture (Table 1). For IL-4, the three groups 
showed no significant differences. The level of IL-5 
was increased in NP in comparison to CRSsNP, while a 
comparison between either of both groups of chronic 
rhinosinusitis versus controls revealed no differences. 
As shown in Fig.  1, CRSsNP (median 15  pg/ml, range 
2–92 pg/ml; p < 0.01 vs. controls and vs. NP) as well as 
NP (median 10  pg/ml, range 4–62  pg/ml; p  <  0.001 vs. 
controls) presented reduced amounts of IL-13 (controls: 
median 19 pg/ml, range 10–32 pg/ml).
Compared to the controls and CRSsNP, the quanti-
ties of TH1 associated cytokines IL-12 (Fig.  2a), as well 
as IFN-γ (Fig. 2b) were decreased in NP (IL-12: median 
108  pg/ml, range 17–211  pg/ml, p  <  0.001 vs. con-
trols and vs. CRSsNP; INF-γ median 63  pg/ml, range 
0–308  pg/ml, p  <  0.001 vs. controls and p  <  0.01 vs. 
CRSsNP). CRSsNP (IL-12: median 158  pg/ml, range 
60–318 pg/ml; INF-γ median 102 pg/ml, range 0–683 pg/
ml) did not differ from the controls (IL-12: median 
200  pg/ml, range 59–358  pg/ml; INF-γ median 107  pg/
ml, range 34–551 pg/ml).
Likewise, IL-10 (Fig.  3), a Treg related cytokine, was 
decreased in NP (median 41  pg/ml, range 8–72  pg/
ml) compared to controls (median 73  pg/ml, range 
31–158 pg/ml; p < 0.001) as well as to CRSsNP (median 
74 pg/ml, range 20–118 pg/ml; p < 0.001).
In contrast to these diminished cytokine levels, the 
TH17 respective cytokine IL-17 (Fig.  4) was elevated 
in nasal secretions of NP patients (median 15  pg/ml, 
range 0–105  pg/ml) in comparison to controls (median 
2 pg/ml, range 0–320 pg/ml; p < 0.001) and to CRSsNP 
(median 2 pg/ml, range 0–146 pg/ml; p < 0.001).
Mast cell activation was seen in NP patients by ele-
vated levels of tryptase in nasal secretion, as indicated 
in Fig.  5a (NP median 11  pg/ml, range 0–75  pg/ml; 
controls: median 0  pg/ml, range 0–94  pg/ml; CRSsNP 
median 0  pg/ml, range 0–75  pg/ml; p  <  0.001 vs. con-
trols). Additionally, ECP (Fig.  5b), a marker of eosino-
phil activation, was increased in NP (NP median 56 pg/
ml, range 0–1000  pg/ml; controls: median 20  pg/ml, 
Table 1 Cytokine levels in nasal fluid in healthy controls, NP and CRSsNP participants
Concentrations are given in pg/ml. Data are presented as median (upper line) and range (lower line). To control the false discovery rate, we used the method of 
Benjamini and Yukatieli. Thus, values marked with ‘*’ are regarded as non-significant despite p < 0.05
n.s. not significant; s. significant
























































 NP—Con n.s. (0.822) n.s. (0.070) n.s. (0.562) s. (< 0.001) n.s. (0.114) n.s. (0.286) n.s. (0.447) s. (< 0.001) s. (< 0.001)
 CRSsNP—Con n.s. (0.133) n.s. (0.025)* n.s. (0.291) s. (< 0.01) n.s. (0.361) n.s. (0.456) s. (< 0.050) n.s. (0.028)* n.s. (0.028)*
 NP—CRSsNP n.s. (0.213) s. (<0.001) n.s. (0.887) s. (< 0.01) n.s. (0.315) n.s. (0.148) n.s. (0.079) n.s. (0.024)* n.s. (0.037)*
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range 0–467  pg/ml; CRSsNP median 45  pg/ml, range 
0–1000 pg/ml; p < 0.001) while the quantity of eotaxin in 
nasal discharge showed no statistically significant differ-
ences among groups (Table 1).
Neutrophil associated factors such as IL-8 (Table  1) 
partially showed a non-significant elevation in nasal 
secretion from patients with chronic rhinosinusitis 
either with or without nasal polyps. While in NP G-CSF 
(Fig.  6) was increased threefold over the controls (NP 
median 277 pg/ml, range 0–9802 pg/ml; controls: median 
90 pg/ml, range 9–7962 pg/ml; CRSsNP: median 155 pg/
ml, range 0–8611  pg/ml; p  <  0.01), levels of GM-CSF 
(Table 1) were not different among groups.
Quantities of chemoattractant proteins were increased 
in chronic rhinosinusitis. MCP-1 and MIP-1α were sig-
nificantly elevated in NP only (Table 1). Irrespective of the 
existence of nasal polyps, levels of MIP-1β (Fig.  7) were 
significantly increased in NP (median 251  pg/ml, range 

















Fig. 1 Levels of IL-13 in nasal fluid in controls, NP and CRSsNP: box 
plots of the levels of IL-13 in nasal secretion is shown. IL-13 is signifi-
cantly decreased in NP compared to both CRSsNP and the controls. 
Moreover, IL-13 is decreased in CRSsNP compared to the controls. 


































Fig. 2 Levels of IL-12 and IFN-γ in nasal fluid in controls, NP and CRSsNP: box plots of the levels of IL-12 (a dark grey) and IFN-γ (b light grey) in nasal 
















Fig. 3 Levels of IL-10 in nasal fluid in controls, NP and CRSsNP: box 
plot of IL-10 levels in nasal secretion is shown. IL-10 is significantly 
decreased in NP compared to the controls as well as to CRSsNP. 
***p < 0.001
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182  pg/ml, range 0–5296  pg/ml; p  <  0.01) over controls 
(median 103  pg/ml, range 0–2049  pg/ml). Concerning 
RANTES, a statistically significant increase was found 
only in CRSsNP compared to the controls, whereas levels 
in NP did not differ from the other groups (Table 1).
Discussion
This study is part of an extensive project, aiming for dis-
tinct cytokine patterns in chronic nasal diseases. CRS 
seems to be a heterogeneous group of diseases presenting 
not only different phenotypes like CRS with or without 
nasal polyps but also consisting of diverse endotypes. 
New therapeutic approaches with biologic agents are cur-
rently in development [17]. These new approaches neces-
sitate patient selection by biomarkers. To determine this 
reason, there is demand for tools helping to define endo-
types as well as to select suitable patients for therapies 
with anti-cytokine antibodies. Bio-Plex Cytokine Assay in 
nasal secretion could be such a tool as collection of nasal 
discharge is an easy procedure harmless to the patient, 
and the assay is simple to perform. Thus, it constitutes a 
methodological approach possibly applicable in clinical 
routine. We therefore have already analysed cytokines 
in nasal secretions of patients with allergic rhinitis in a 
true-to-life clinical setting as a first step [18]. In the pre-
sent study, we measured the amount of cytokines in nasal 
fluid of participants suffering from NP or CRSsNP as well 
as healthy controls. The aim of the current study was to 
investigate whether in CRS with or without nasal polyps, 
representative cytokines in nasal discharge show distinct 
patterns proving the used methodology helpful for endo-
typing inflammatory nasal diseases. In the long term, we 
aim for providing easily accessible biomarkers allocating 
patients to specific endotypes and therapies.
IL-4, IL-5, and IL-13 are usually regarded as TH2 
cytokines, being predominantly involved in the humoral 
immune response. These cytokines are not only pro-
duced by TH2 lymphocytes but also by other cells 
involved in this response pattern, such as plasma cells, 
mast cells, and eosinophils [10, 19]. For IL-4, we did not 
find any differences between the three groups, which is in 
accordance with previous findings [20]. However, other 

















Fig. 4 Levels of IL-17 in nasal fluid in controls, NP and CRSsNP: 
box plot of IL-17 levels in nasal secretion is shown. IL-17 is signifi-

































Fig. 5 Levels of tryptase and ECP in nasal fluid in controls, NP and CRSsNP: box plots of the levels of tryptase (a dark grey) and ECP (b light grey) in 
nasal secretion are shown. Tryptase and ECP are significantly elevated in NP compared to controls. ***p < 0.001
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and a correlation between IL-4 levels and the patients’ 
CT scores was described [21, 22]. IL-4, as well as IL-13, 
supports the expression of a TH2 inflammatory pat-
tern by modulating lymphocyte differentiation, inducing 
IgE production, and facilitating eosinophil infiltration 
by the up-regulation of chemoattractants and adhesion 
molecules [19, 23]. Moreover, in  vitro studies revealed 
a negative influence of IL-4 on the epithelial integrity in 
NP [24]. We surprisingly found decreased levels of IL-13 
in both CRS groups, contradicting previous reports of an 
up-regulation of IL-13 mRNA in NP [22, 25]. Using the 
same control group, we unexpectedly detected decreased 
levels in allergic rhinitis patients in a previous study [18]. 
This might imply a methodical error forming the basis of 
the decreased amounts of IL-13. We are not able to offer 
a suitable concept for this unexpected result. Concern-
ing IL-5, detected levels in CRSsNP and NP were not sig-
nificantly different from controls. However, the amount 
of IL-5 in NP secretions was significantly higher than in 
CRSsNP. Several authors found elevated levels of this 
cytokine [25–27]. IL-5 is a hematopoietic growth factor 
and crucial for the survival and maturation of eosinophils 
at the site of inflammation [19, 23]. Therefore, it is dis-
cussed as a possible therapeutic target in NP and studies 
with anti-IL-5 monoclonal antibodies show auspicious 
results [28].  In conclusion, our results indicate a down-
regulation of TH2 lymphocytes in CRSsNP. Furthermore, 
they rebut an expected up-regulation in NP and are 
opposed to the general assumption that the majority of 
Caucasian NP patients show a TH2 pattern of inflamma-
tion with elevations of TH2-type cytokines.
IL-12 and IFN-γ are indicators of TH1 lymphocyte 
activity. Both cytokines were decreased in NP compared 
to both the controls and CRSsNP, indicating a down-
regulation of TH1 cells in nasal polyposis. Others found 
up-regulated or unchanged levels of IFN-γ and IL-12 in 
NP and CRSsNP [27, 29]. However, these studies used 
tissue samples instead of nasal secretions. Both IL-12 and 
IFN-γ induce a predominantly cellular immune response, 
involving cytotoxic cells and macrophages. They pro-
mote TH1 differentiation and counteract TH2 and TH17 
development [30]. Moreover, they influence neutrophil 
survival as well as epithelial integrity [24, 31]. In a study 
on mice, IFN-γ expression was shown to be associated 
with deteriorated olfactory function [32]. Accordingly, 
this cytokine might be considered a therapeutic target for 
treating the burdensome reduction of smell in patients 
suffering from CRS.
IL-10 was used as a reference to the role of Treg in 
CRS. A decrease was detected in NP which fits the find-
ings of Kim et  al. who detected impaired migration of 
regulatory T cells in NPs [33]. This points to a derogated 
immunomodulation in the mucosa of NPs. Furthermore, 
the level of IL-17 was sevenfold higher in NP than in the 
controls or CRSsNP. IL-17 is characteristic for TH17 lym-
phocytes and a proinflammatory cytokine affecting neu-
trophils and eosinophils [34, 35]. Data on IL-17 is still 
ambiguous. While elevated levels have been described 
in Chinese NP patients, studies on Caucasians reveal 
conflicting results, ranging from elevated to reduced 
amounts [12, 25, 36]. Thus, further research on this 
topic might be needed. In conjunction with the afore-
















Fig. 6 Levels of G-CSF in nasal fluid in controls, NP and CRSsNP: box 
plot of G-CSF levels in nasal secretion. G-CSF is significantly elevated 
















Fig. 7 Levels of MIP-1β in nasal fluid in controls, NP and CRSsNP: box 
plot of MIP-1β levels in nasal secretion. MIP-1β is significantly elevated 
in NP and CRSsNP compared to controls. **p < 0.01, ***p < 0.001
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over TH1 as well as an up-regulation of TH17 was seen 
in NP while an impaired function of Treg suggests itself 
in this disease entity. CRSsNP, however, showed normal 
quantities of all cytokines except for decreased levels 
of the TH2 cytokine IL-13. Our results argue for a more 
severe inflammation in NP, whereas the inflammation in 
CRSsNP was only weakly depicted in nasal secretions.
Eosinophilic inflammation has frequently been described 
in the nasal mucosa of patients suffering from NP. As men-
tioned, IL-5, a cytokine inducing survival and activation 
of eosinophils was elevated in NP compared to CRSsNP. 
Another major factor in eosinophilic inflammation is 
eotaxin. It is up-regulated preferably by TH2 and potently 
attracts eosinophils [10, 37, 38]. Elevated levels were found 
in the sinunasal mucosa of CRS patients as well as in nasal 
secretions of NP patients [27, 39]. In our study highest lev-
els were also seen in NP, however differences between the 
three groups did not reach statistical significance. The lev-
els of ECP, on the other hand, were significantly elevated in 
NP but not in CRSsNP. ECP is a protein holding antimicro-
bial as well as modulatory properties [40]. Plenty of reports 
of elevations of ECP levels in different nasal diseases exist, 
indicating that ECP is rather a general marker of inflamma-
tion than disease-specific [14, 29, 41]. Our results suggest 
an infiltration of eosinophils into the mucosa of nasal pol-
yps but not into the mucosa of CRSsNP. In allergic rhinitis, 
mast cells have frequently been investigated, and much is 
known about their role in the early-phase of allergic reac-
tion [42]. We detected elevated levels of tryptase in nasal 
secretions of the NP patients. This is in conformity with 
findings from others describing an increased amount of 
mast cells and tryptase in mucosal tissue and nasal secre-
tions of NP patients. Further, the level of tryptase in nasal 
secretions correlated with nasal obstruction and rhinor-
rhoea [14, 43]. This might suggest a benefit from mast cell 
targeting medication in NP.
Di Lorenzo and colleagues reported that the levels of 
tryptase and ECP in NP exceeded those in allergic rhini-
tis [44]. We compared the levels of these two mediators 
in NP with the previously reported levels in allergic rhi-
nitis (AR) [18]. For ECP and tryptase, the levels in sea-
sonal AR were twice as high as in NP, while the values in 
perineal AR were slightly lower than in NP. However, in 
contrast to the findings of Di Lorenzo and co-workers, 
in our study, the differences between the levels in NP 
and AR did not reach statistically significance. Di Lor-
enzo et al. gained their samples by nasal lavage while we 
used the cotton wool method. ECP release was found 
to be higher in polyps than in the lower turbinate of NP 
patients [45]. Probably, the amount of ECP and tryptase 
would be higher under assured placement of the cotton 
wool pieces on the polyp. This might explain the differ-
ence to Di Lorenzo’s results.
Neutrophil infiltration has been seen in both CRSsNP 
and NP [46]. In order to get indication of neutrophil 
attraction, we measured the levels of IL-8 and detected 
elevated amounts in both CRS groups but not reaching 
a level of significance. Others report a more pronounced 
increase of IL-8 in NP [47, 48].
The colony-stimulating factors delay neutrophil death 
[31]. While G-CSF influences proliferation and differen-
tiation of neutrophil progenitor cells as well as the func-
tion of mature neutrophils, GM-CSF often appears in 
the context of recruitment, activation, and survival of 
eosinophils [38, 49]. Concerning G-CSF, we found levels 
threefold higher in NP than in controls. GM-CSF was in 
a normal range in the nasal secretions in CRS, irrespec-
tive of nasal polyps, as opposed to elevations described 
in tissue samples of NP patients [50]. In summary, we saw 
no definite evidence of increased neutrophil attraction by 
IL-8, but elevated levels of G-CSF in NP might indicate a 
role of this type of granulocyte in polyposis.
In addition, different chemokines were examined. 
RANTES was elevated in CRSsNP but not in NP, others 
reported increased levels of RANTES in tissue samples of 
polyps [50, 51]. RANTES is known to attract eosinophils, 
basophils and mast cells, and is present in nasal secre-
tions during ongoing infection [38, 52, 53]. Plasma lev-
els of RANTES have been found to correlate with disease 
severity [54]. In contrast to RANTES, we found MCP-1 
to be elevated in NP. MCP-1 attracts different inflamma-
tory cells, among them monocytes and T cells. In CRS, 
increased amounts of MCP-1 have been reported in nasal 
secretions as well as in nasal mucosa biopsies [29, 55].
Two other chemokines, MIP-1α and MIP-1β, are struc-
turally related proteins, with 68  % of their amino acids 
being identical [56]. Produced by a host of inflammatory 
cells, they both have a number of cellular targets, such 
as monocytes and dendritic cells. However, only MIP-1α 
is ascribed to attract granulocytes [56, 57]. In our study, 
increased amounts of MIP-1α were detected in poly-
posis patients while being undetectable in the majority 
of the CRSsNP patients and controls. MIP-1β, on the 
other hand, showed elevated levels in both CRSsNP and 
NP. Peric and co-workers found a correlation between 
MIP-1α levels in nasal secretions and endoscopic and 
CT scores in NP [57]. Moreover, MIP-1α gene expression 
was elevated in patients with early recurrence of polyps 
after surgery over those being treatment-responsive [50]. 
Further research is needed to evaluate the diagnostic and 
prognostic utility of this chemokine in CRS.
In conclusion, the evaluation of the chemokines and 
growth factors in the present study revealed an eleva-
tion of G-CSF, MCP-1, MIP-1α, and MIP-1β in NP, 
while CRSsNP shows increased levels of RANTES and 
MIP-1β only. We conclude that a number of different 
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inflammatory cells are involved in NP and inflammation 
is more pronounced in NP than in CRSsNP.
Conclusions
Colleagues from Belgium recently emphasised in their 
review “Emerging biologics for the treatment of chronic 
sinusitis”: “The greatest challenge for the future is to 
define the different endotypes of CRSwNP using eas-
ily accessible biomarkers to select the patients who have 
the best chance of a positive therapeutic response to 
innovative approaches.” [58]. With the present study, we 
tried to take a closer look exactly on this topic evaluating 
cytokine profiles in participants suffering from CRS with 
or without nasal polyps.
Overall, we found a more pronounced inflammatory 
profile in NP than in CRSsNP. IL-5, IL-10, IL-12, IL-17, 
and IFN-γ represent a disequilibrium of T cells in NP, 
and ECP, tryptase, G-CSF, MCP-1, MIP-1α, and MIP-1β 
depict the activation of various inflammatory cells in this 
disease entity. CRSsNP participants, on the other hand, 
did not differ much from healthy individuals. Merely 
RANTES and MIP-1β seem to be suitable mediators to 
distinguish between CRSsNP and healthy individuals. 
As we did not detect any significant differences between 
the three groups for IL-4, IL-8, GM-CSF, and eotaxin, we 
conclude that these mediators are not of distinctive func-
tion in chronic rhinosinusitis.
In the long term, we aim to evaluate multiplex-analyses 
of cytokines in nasal discharge being a suitable diagnostic 
tool for the “endotyping” of patients with chronic sinona-
sal diseases. To us, this is a crucial step for selection of 
patients with regard to a therapy with biologic agents, 
especially anti-cytokine antibodies. The sampling of nasal 
secretions is an easily performable and non-invasive 
method and could benefit many patients if established 
as a diagnostic and prognostic tool. However, further 
research regarding suitable indicators of different nasal 
diseases and the establishment of norm values is needed 
to attain this goal. Thus, therapies tailored to the indi-
vidual patient’s needs should become accessible in the 
future.
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